School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China.
Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China.
Molecules. 2018 Jan 27;23(2):252. doi: 10.3390/molecules23020252.
In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (- and -) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, , which was 200- and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC = 0.035 μM against human URAT1 for vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.
为了系统地探索和更好地理解二芳基甲烷骨架在设计强效尿酸盐转运蛋白 1 (URAT1) 抑制剂中的构效关系 (SAR),设计并合成了 33 种化合物 (- 和 -),并测定了它们对 URAT1 的体外抑制活性 (IC)。三轮系统的 SAR 探索发现了一种高效的新型 URAT1 抑制剂 ,对人 URAT1 的抑制活性分别比母药 lesinurad 和苯溴马隆高 200 倍和 8 倍(IC = 0.035 μM 对 vs. 7.18 μM 和 0.28 μM 对 lesinurad 和苯溴马隆,分别)。化合物 是迄今为止我们实验室发现的最有效的 URAT1 抑制剂,与目前临床试验中开发的最有效的抑制剂相当。本研究表明,二芳基甲烷骨架是设计强效 URAT1 抑制剂的非常有前途的分子支架。